Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome

Enasidenib is an FDA-approved isocitrate dehydrogenase 2 (IDH2) inhibitor, which is used in the treatment of acute myeloid leukemia (AML). We present a case of AML with an IDH2 mutation treated with a regimen of enasidenib and 5-azacitidine, where thyroiditis was noted to be a part of differentiatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Annamaraju, Pavan, Gopishetty, Swathi, Goparaju, Naga, Beasey, Matthew, Kota, Vamsi, Guddati, Achuta K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275196/
https://www.ncbi.nlm.nih.gov/pubmed/32547385
http://dx.doi.org/10.1159/000507613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275196/
https://www.ncbi.nlm.nih.gov/pubmed/32547385
http://dx.doi.org/10.1159/000507613

Ejemplares similares